Medtronic ( (MDT) ) has released its Q2 earnings. Here is a breakdown of the information Medtronic presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Medtronic plc, headquartered in Galway, Ireland, is a leading global healthcare technology company dedicated to addressing significant health challenges through innovative solutions in various medical fields.
In its latest earnings report for the second quarter of fiscal year 2025, Medtronic showcased strong financial performance, surpassing expectations and raising its guidance, driven by innovation across its diverse product portfolios.
The company reported a revenue of $8.4 billion, reflecting a 5.3% increase as reported and a 5.0% increase on an organic basis. The GAAP diluted earnings per share (EPS) rose to $0.99, a 46% increase, while non-GAAP diluted EPS reached $1.26. Key growth areas included the Cardiovascular and Neuroscience portfolios, with significant advancements in products such as the Micra™ transcatheter pacing systems and the Percept™ RC deep brain stimulator.
Medtronic’s Diabetes segment saw a notable 12.4% revenue increase, driven by the adoption of the MiniMed™ 780G system. The company also raised its fiscal year 2025 revenue growth guidance to 4.75% to 5% and adjusted EPS guidance, indicating confidence in sustained growth.
Moving forward, Medtronic remains optimistic, focusing on margin improvements and leveraging its robust pipeline in high-impact markets to continue delivering strong results and expanded patient care worldwide.
